<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <body>
  <table style="border: 1px solid black;">
   <caption/>
   <tr>
    <th style="border: 1px solid black;">Study type (CONSORT/STROBE) </th>
    <th style="border: 1px solid black;">Main cancer class </th>
    <th style="border: 1px solid black;">CIPN severity report (count by grade if given) </th>
    <th style="border: 1px solid black;">CIPN assessment time points </th>
    <th style="border: 1px solid black;">CIPN assessment method(s) </th>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Von Schlippe (2001) </td>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">Testicular </td>
    <td style="border: 1px solid black;">Grade I (4/5) </td>
    <td style="border: 1px solid black;">Unclear if at baseline </td>
    <td style="border: 1px solid black;">NPS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Cisplatin or carboplatin and paclitaxel: 73% (95% CI = 36.2–109.7) </td>
    <td style="border: 1px solid black;">Grade II (1/5) </td>
    <td style="border: 1px solid black;">Every 6 wk for first 6 mo after chemotherapy </td>
    <td style="border: 1px solid black;">PNS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Argyriou (2007) </td>
    <td style="border: 1px solid black;">Mild (2/9) </td>
    <td style="border: 1px solid black;">Thereafter every 2 mo for median of 4 y (range </td>
    <td style="border: 1px solid black;">NPS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">Moderate (6/9) </td>
    <td style="border: 1px solid black;">2–8 y) </td>
    <td style="border: 1px solid black;">NCI-CTC </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Multiple solid </td>
    <td style="border: 1px solid black;">Severe (1/9) </td>
    <td style="border: 1px solid black;">Baseline </td>
    <td style="border: 1px solid black;">(EORTC) QLQ-C30 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Kawakami (2012) </td>
    <td style="border: 1px solid black;">% Severity with </td>
    <td style="border: 1px solid black;">Cycle 3, 6 </td>
    <td style="border: 1px solid black;">NES </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{§} </td>
    <td style="border: 1px solid black;">cumulative dose </td>
    <td style="border: 1px solid black;">3 mo after chemo end </td>
    <td style="border: 1px solid black;">PNS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">Only grade P3 reported </td>
    <td style="border: 1px solid black;">Baseline </td>
    <td style="border: 1px solid black;">NPS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Lung </td>
    <td style="border: 1px solid black;">Reported by age group </td>
    <td style="border: 1px solid black;">Daily during cycle 1 </td>
    <td style="border: 1px solid black;">NCI-CTC </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Cisplatin and vincristine: 20.1% (95% CI = -26.2 to 66.5) </td>
    <td style="border: 1px solid black;">only </td>
    <td style="border: 1px solid black;">Cycle 2, 3, 4 </td>
    <td style="border: 1px solid black;">TNSc </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Glendenning (2010) </td>
    <td style="border: 1px solid black;">Only grade P2 reported </td>
    <td style="border: 1px solid black;">Chemo end </td>
    <td style="border: 1px solid black;">NPS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{§} </td>
    <td style="border: 1px solid black;">Mild (10/16) </td>
    <td style="border: 1px solid black;">Recruited patients at least 5 y post-treatment </td>
    <td style="border: 1px solid black;">TNSc </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Cross-sectional </td>
    <td style="border: 1px solid black;">Moderate (5/16) </td>
    <td style="border: 1px solid black;">Assessed once for this prevalence study </td>
    <td style="border: 1px solid black;">NPS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Testicular </td>
    <td style="border: 1px solid black;">Severe (1/16) </td>
    <td style="border: 1px solid black;">Baseline </td>
    <td style="border: 1px solid black;">NCI-CTC </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">cohort </td>
    <td style="border: 1px solid black;">Mean neurotoxicity scores </td>
    <td style="border: 1px solid black;">Cycles 3, 6 </td>
    <td style="border: 1px solid black;">NCI-CTC </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Paclitaxel: 70.8% (95% CI = 43.5–98.1) </td>
    <td style="border: 1px solid black;">reported </td>
    <td style="border: 1px solid black;">3 mo after chemo end </td>
    <td style="border: 1px solid black;">NCI-CTC </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Argyriou (2006) </td>
    <td style="border: 1px solid black;">Grade P I 31.8% </td>
    <td style="border: 1px solid black;">Unclear if at baseline </td>
    <td style="border: 1px solid black;">NPS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{‡} </td>
    <td style="border: 1px solid black;">Grade P II 11% </td>
    <td style="border: 1px solid black;">Cycles 4, 6 </td>
    <td style="border: 1px solid black;">NCI-CTC </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">Grade P III 3.6% </td>
    <td style="border: 1px solid black;">Within 1 mo of chemo end </td>
    <td style="border: 1px solid black;">TNSc </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Breast </td>
    <td style="border: 1px solid black;">Grade details not reported </td>
    <td style="border: 1px solid black;">Baseline </td>
    <td style="border: 1px solid black;">NPS </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Baldwin (2012) </td>
    <td style="border: 1px solid black;">Grade I (12/24) </td>
    <td style="border: 1px solid black;">1 mo after chemo end </td>
    <td style="border: 1px solid black;">Skin biopsy </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">Grade II (6/24) </td>
    <td style="border: 1px solid black;">Baseline </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Breast </td>
    <td style="border: 1px solid black;">Subclincial (6/24) </td>
    <td style="border: 1px solid black;">After 12 wk of chemo </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Ghoreishi (2012) </td>
    <td style="border: 1px solid black;">Grade I NR </td>
    <td style="border: 1px solid black;">After 24 wk of chemo </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">RCT </td>
    <td style="border: 1px solid black;">Grade II (64/159) </td>
    <td style="border: 1px solid black;">Unclear if at baseline </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Breast </td>
    <td style="border: 1px solid black;">Grade III (45/159) </td>
    <td style="border: 1px solid black;">At each cycle </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Pace (2007) </td>
    <td style="border: 1px solid black;">Grade IV (1/159) </td>
    <td style="border: 1px solid black;">For 6 months after chemo end for induction (ie, </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">Grade P2 reported </td>
    <td style="border: 1px solid black;">36 wk from start of induction therapy) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Breast </td>
    <td style="border: 1px solid black;">Unclear if at baseline </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Vincristine: 19.6% (95% CI -26.6 to 65.9) </td>
    <td style="border: 1px solid black;">At each cycle </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Johnson (2011) </td>
    <td style="border: 1px solid black;">For 6 mo after end of chemo for induction (ie, </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{‡} </td>
    <td style="border: 1px solid black;">36 weeks from start of induction therapy) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">RCT </td>
    <td style="border: 1px solid black;">Baseline </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Multiple </td>
    <td style="border: 1px solid black;">After 4 mo of chemo </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">myeloma </td>
    <td style="border: 1px solid black;">3 mo after stem cell transplantation </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Thalidomide: 63.5% (95% CI = 29.3–97.8) </td>
    <td style="border: 1px solid black;">Unclear if at baseline </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Johnson (2011) </td>
    <td style="border: 1px solid black;">Every 3 wk until </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">^{‡} </td>
    <td style="border: 1px solid black;">1 mo after last chemo dose </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">RCT </td>
    <td style="border: 1px solid black;">Longer follow-up but no denominator data </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Multiple </td>
    <td style="border: 1px solid black;">Baseline </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">myeloma </td>
    <td style="border: 1px solid black;">Cycles 2, 4, 6, 8 </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Plasmati (2002) </td>
    <td style="border: 1px solid black;">End of chemo </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Prospective cohort </td>
    <td style="border: 1px solid black;">Note skin biopsy at baseline and end of chemo </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Multiple </td>
    <td style="border: 1px solid black;">only </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">myeloma </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Bortezomib: 46.7% (95% CI = 0.3–93.1) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Dimopoulos (2011) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">RCT </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Multiple </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">myeloma </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Bortezomib and thalidomide: 96.2% (95% CI = 49.7–143) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Chaudhary (2008) </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Prospective cohort </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">Multiple </td>
   </tr>
   <tr>
    <td style="border: 1px solid black;">myeloma </td>
   </tr>
  </table>
 </body>
</html>
